Abdel-Wahab N, Talathi S, Lopez-Olivo M A, Suarez-Almazor M E
1 Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The 4002 University of Texas MD Anderson Cancer Center , Houston, TX, USA.
2 Rheumatology and Rehabilitation Department, Assiut University Hospitals, Faculty of Medicine, Assiut, Egypt.
Lupus. 2018 Apr;27(4):572-583. doi: 10.1177/0961203317731532. Epub 2017 Sep 24.
Objective The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection. Method We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included. Results We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6-19.4), as were those with HCV (RR 6.3, 95% CI 3.9-10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8-9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4-22.2). The only statistically significant increased risk for anti-β2-glycoprotein I (anti-β2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0-22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3-2.6), and those with EBV, elevated anti-β2-GPI antibodies (RR 2.2, 95% CI 1.3-3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0-18.1), and HBV (5.9%, 95% CI 2.0-11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78-45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL. Conclusions Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information.
目的 本文旨在对病毒感染后抗磷脂(aPL)抗体升高及相关血栓栓塞和/或妊娠事件发生风险进行系统评价和荟萃分析。方法 检索截至2016年6月的Medline、EMBASE、Web of Science、PubMed电子出版物和Cochrane对照试验中央注册库。纳入病毒感染患者与对照组或狼疮患者相比aPL抗体升高的独立观察性研究。结果 我们分析了60项研究的73篇出版物。最常报道的是人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)。与健康对照组相比,HIV患者更易出现抗心磷脂(aCL)抗体升高(风险比(RR)10.5,95%置信区间(CI)5.6 - 19.4),HCV患者(RR 6.3,95% CI 3.9 - 10.1)、乙型肝炎病毒(HBV)患者(RR 4.2,95% CI 1.8 - 9.5)和EB病毒(EBV)患者(RR 10.9,95% CI 5.4 - 22.2)也是如此。仅在HCV患者中观察到抗β2糖蛋白I(抗β2-GPI)抗体有统计学意义的风险增加(RR 4.8,95% CI 1.0 - 22.3)。与狼疮患者相比,HIV患者更易出现aCL抗体升高(RR 1.8,95% CI 1.3 - 2.6),EBV患者更易出现抗β2-GPI抗体升高(RR 2.2,95% CI 1.3 - 3.9)。血栓栓塞事件在aPL抗体升高且感染HCV(9.1%,95% CI 3.0 - 18.1)和HBV(5.9%,95% CI 2.0 - 11.9)的患者中最为普遍,妊娠事件在感染细小病毒B19的患者中最为普遍(16.3%,95% CI 0.78 - 45.7)。然而,与aPL抗体阴性的病毒感染患者相比,仅在HCV且aPL抗体阳性的患者中观察到有统计学意义的风险增加。结论 病毒感染可增加aPL抗体升高及相关血栓栓塞事件的发生风险。结果取决于所报告的信息。